Key Market Indicators
Swedish blood and blood forming organs medicine sales are set to reach $648 million by 2026, a 1.7% year-on-year average growth since 2005. In 2021, Sweden was ranked 11th, overtaken by Australia at $584 million. Germany, Italy, and South Korea followed as the second, third, and fourth largest markets. Swedish anemia prevalence is set to decrease by 0.9% year-on-year CAGR to 8,270 hospital discharges by 2026. Since 2005, Swedish demand has decreased by 1.5% year-on-year. In 2021, Israel took the lead at 8,690 hospital discharges, and Germany, the United Kingdom, and Poland followed as numbers two, three, and four.
